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Nrf2Increased oxidative stress and cardiac inﬂammation have been implicated in the pathogenesis of diabetic cardio-
myopathy (DCM). We previously found that a novel chalcone derivative, L6H9, was able to reduce LPS-induced
inﬂammatory response inmacrophages. This studywas designed to investigate its protective effects on DCM and
the underlying mechanisms. H9C2 cells were cultured with DMEM containing 33 mmol/L of glucose in the
presence or absence of L6H9. Pretreatment with L6H9 signiﬁcantly reduced high glucose-induced inﬂammatory
cytokine expression, ROS level increase, mitochondrial dysfunction, cell apoptosis, ﬁbrosis, and hypertrophy in
H9c2 cells, which may be mediated by NF-κB inhibition and Nrf2 activation. In mice with STZ-induced diabetes,
oral administration of L6H9 at 20 mg/kg/day for 8 weeks signiﬁcantly decreased the cardiac cytokine and ROS
level, accompanied by decreasing cardiac apoptosis and hypertrophy, and, ﬁnally, improved histological
abnormalities and ﬁbrosis, without affecting the hyperglycemia. L6H9 also attenuated the diabetes-induced
NF-κB activation and Nrf2 decrease in diabetic hearts. These results strongly suggest that L6H9 may have great
therapeutic potential in the treatment of DCM via blockage of inﬂammation and oxidative stress. This study
also provides a deeper understanding of the regulatory role of Nrf2 and NF-κB in DCM, indicating that they
may be important therapeutic targets for diabetic complications.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Diabetic cardiomyopathy (DCM), one of the leading cardiovascular
complications in diabetic patients, has gained much interest due to its
subsequent heart failure and eventually increased mortality [1,2]. As
DCM has become an increasingly recognized entity among clinicians, a
better understanding of its pathophysiology and pharmacological
intervention is necessary for early diagnosis and the development of
new treatment strategies. The pathophysiology of DCM is believed to
be multifactorial. Hyperglycemia, the primary clinical manifestation of
diabetes, as a major etiological factor, has been demonstrated to induce
multiple alterations and ultimately lead to diabetic cardiomyopathy
in vitro and in vivo [1]. Several mechanisms have been implicated inL6H9, (E)-2,6-diﬂuoro-4′-
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tor
wzmcliangguang@163.comthe pathogenesis of DCM, including increased oxidative stress, cardiac
inﬂammation, mitochondrial dysfunction, cardiac cell apoptosis,
interstitial ﬁbrosis, and left ventricular hypertrophy [3]. Among these
events, the oxidative stress and inﬂammation seem to be the upstream
of the cascade. Recent studies also indicated that the oxidative stress
and inﬂammation can cross-talk and contribute to each other [4].
Therefore, anti-oxidative and anti-inﬂammatory therapies appear to
be promising approaches in dealingwith DCMpatients. Although several
small molecules with anti-oxidant or anti-inﬂammatory property have
shown the protection against DCM, to ﬁnd novel therapeutic agents for
the treatment of DCM is still timely [5,6].
Natural products may help the identiﬁcation of bioactive lead
compounds for treating oxidative and inﬂammatory diseases. Chalcones,
considered as the precursors of ﬂavonoids and isoﬂavonoids, are
abundant in edible plants, and have also been shown to display a diverse
array of pharmacological activities including anti-inﬂammatory,
anti-microbial, anti-fungal, anti-oxidant, cytotoxic, anti-tumor and anti-
cancer activities [7]. Recent reports indicate the importance of chalcones
as potential therapeutic agents in cardiovascular system diseases [8]. The
structure of chalcone is also an excellent leading skeleton for modern
drug design and development. During the past decades, synthetic
modiﬁcations of chalcones to enhance their bioactivities and develop
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hydroxychalcones and 3,4-dihydoxychalcones as anti-inﬂammatory
agents and isoprenylchalcone and naringeninchalcone as anti-oxidative
agents [9,10] (Fig. 1A). Our group has previously designed and synthe-
sized a series of chalcone derivatives and then evaluated their
anti-inﬂammatory property against TNF-α and IL-6 production in
LPS-stimulated macrophages [11]. Among these chalcones, compound
(E)-2,6-diﬂuoro-4′-methoxychalcone (L6H9, Fig. 1A) exhibited signiﬁ-
cant therapeutic effects against LPS-induced inﬂammatory response
both in vitro and in vivo, suggesting its potential to serve as a new
anti-inﬂammatory agent [11]. Importantly, L6H9 is well tolerated with-
out side effects when chronically administered tomice (data not shown).
Therefore, we have investigated the potential protective effects of
L6H9 in diabetic hearts and in cultured cardiomyocytes exposed to
high glucose. Curcumin, a constituent of the spice turmeric showing
multifunctional pharmacological effects in diseases including DCM,
[12] was used as a positive agent in this work. Our ﬁndings revealed
the potential of L6H9 for the prevention of diabetic complications via
blockage inﬂammation and oxidative stress.
2. Materials and methods
2.1. Cell culture and treatment
H9c2 embryonic rat heart-derived cell line was obtained from the
Shanghai Institute of Biochemistry and Cell Biology (Shanghai, China)
and cultured in DMEMmedium (Gibco, Eggenstein, Germay) containing
5.5 mmol/L of D-glucose supplemented with 10% FBS, 100 U/mL of pen-
icillin, and 100 mg/mL of streptomycin. In the high glucose-treated
group (HG), cells were incubated with a DMEM medium containing
33 mmol/L of glucose. Curcumin was purchased from Sigma (St. Louis,
MO). Compound L6H9 was synthesized and puriﬁed (N98.4%) as
described in our previous publication [11]. Curcumin (Cur) and L6H9
were dissolved in DMSO for in vitro experiments and in CMC-Na (1%)
for in vivo experiments.
2.2. Animal studies
The animalswere obtained fromAnimal Center ofWenzhouMedical
University. Protocols used for all animal studies were approved by the
Wenzhou Medical University Animal Policy and Welfare Committee
(Approved documents: wydw2013-0058) and complied with the NIH
guidelines (Guide for the care and use of laboratory animals). Diabetes
mellitus was induced inmale C57BL/6mice 8 to 12weeks old, weighing
23 to 25 g by a single intraperitoneal (i.p.) injection of streptozotocin
(STZ, Sigma Chemicals, St. Louis, MO) at the dose of 100mg/kg dissolved
in 100 mM citrate buffer (pH 4.5). Control animals received buffered
saline alone. One week later, blood glucose levels were measured
using a Glucometer by mandibular vein puncture blood sampling.
Mice with fasting-blood glucose N12 mmol/L were considered diabetic
and were used for the further study. All mice had free access to food
and water at all times. The compound treatment was initiated after
the establishment of frank type 1 diabetes mellitus (insulin-generating
beta cells were already destroyed by the injection of streptozotocin).
STZ-induced diabetic mice (STZ-DM1) were orally treated with
curcumin (Cur, 50 mg/kg), L6H9 (20 mg/kg), or vehicle (CMC-Na) byFig. 1. The structures of chalcone derivative L6H9.gavage once every two days for 8 weeks (n = 8 in each group). The
corresponding control groups were treated with vehicle for the same
duration (n = 8). At the indicated time points, blood glucose was
determined and body weight was recorded. At 56th days after the ﬁrst
treatment, mice were anesthetized with 100 mg/kg bogy weight
ketamine hydrochloride (Ketanest, Pﬁzer, Germany) and 16 mg/kg
body weight xylazine hydrochloride (Rompun 2%, Bayer, Germany).
The mice were killed under anesthesia. The body weight was recorded
and blood samples were collected and centrifuged at 4 °C at 3000 rpm
for 10 min to collect the serum. Heart tissues were embedded in 4%
paraformaldehyde for pathological analysis and/or snap-frozen in liquid
nitrogen for gene and protein expression analysis.
2.3. Western blot analysis
The common procedure for Western blot analysis was described in
previous publication [11]. Antibodies for IκBα, Bax, Bcl-2, GAPDH,
TGF-β, cytochrome C, collagen I, Nrf2, and the secondary horseradish
peroxidase-conjugated antibody were obtained from Santa Cruz
Technology (Santa Cruz, CA). Antibody for TNF-α was purchased from
Abcam (Cambride, MA). The density of the immunoreactive bands was
analyzed using Image J software (NIH, Bethesda, MD). In all western
bolt analysis, GAPDH was used as a loading control protein.
2.4. Reverse transcription and real-time quantitative PCR
Total RNA was isolated from cells and tissues (50–100 mg) using
TRIZOL (Invitrogen, Carlsbad, CA) according to the manufacturer's
instructions. Reverse transcription and quantitative PCR were
performed using M-MLV Platinum RT-qPCR Kit (Invitrogen, Carlsbad,
CA). Real-time qPCR was carried out using the Eppendorf Real plex 4
instrument (Eppendorf, Hamburg, Germany). Primers for genes including
TNF-α, IL-6, COX-2, Nrf2, HO-1, NQO-1, GCLC, TGF-β, collagen1, CTGF,
MMP-2, β-MyHC, ANP, BNP, and β-actin were synthesized in Invitrogen
(Invitrogen, Shanghai, China). The primer sequences usedwere shown in
Table S1. The relative amount of each gene was normalized to the
amount of β-actin.
2.5. Determination of NF-κB andNrf2 activation by electrophoreticmobility
shift assay (EMSA)
Nuclear extracts in H9c2 cells were prepared using the Nuclear and
Cytoplasmic Protein Extraction Kit (KeyGEN Biotech, Nanjing, China)
and protein concentrationswere determined. The EMSAwas performed
using speciﬁc EMSA kits for NF-κB or Nrf2 activity (Beyotime Biotech,
Beijing, China) according to themanufacturer's instructions. The nuclear
protein-oligonucleotide reactions were run on a non-denaturing, 4%
acrylamide 29:1 acrylamide to bisacrylamide) gel, at room temperature.
After electrophoresis, DNA-protein complex was transferred to a nylon
membrane, and cross-linked. Then the biotinylated-labeled DNA
detected by chemiluminescence. The NF-κB conscious oligonucleotides
(double stranded DNA) were: 5′-AGTTGAGGGGACTTTCCCAGGC-3′; the
Nrf2 conscious oligonucleotides (double stranded DNA) were: 5′-CTAC
GATTTCTGCTTAGTCATTGTCTTCC-3′; the sequence of the mutate-ARE
probe was: 5′-ACTGAGGGTGACTCAATAAAATC-3′.
2.6. Immunoﬂuorescence assay for NF-κB p65, TGF-β, and collagen 1
After treatment, H9c2 cells were ﬁxed with 4% paraformaldehyde
and permeabilized with 100% methanol at −20 °C for 5 min. After
ﬁxation and permeabilization, cells were washed twice with PBS
containing 1% BSA and then incubated with primary antibodies for
NF-κBp65, TGF-β, or collagen1 (Santa Cruz Biotech, Santa Cruz, CA) over-
night at 4 °C, followed by FTTC- or PE-conjugated secondary antibody
(Santa Cruz Biotech, Santa Cruz, CA). Then the cells were counterstained
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microscope (200× ampliﬁcation; Nikon, Japan).
2.7. Determination of ROS generation by ﬂuorescent microscope and ﬂow
cytometry
In order to analyze the ROS generation, various subtypes of ROS such
as superoxide (O2−) and hydrogen peroxide (H2O2) were detected
using 2 μMDHE and 2 μMDAF-2DA, respectively, as described previous-
ly [13]. The ﬂuorescence intensity for 10,000 events was acquired using
FACS, and cellular images were captured under the Nikon ﬂuorescence
microscope (400× ampliﬁcation; Nikon, Japan).
2.8. Determination of mitochondrial membrane potential (MMP) and
cytochrome C release
MMP is determined by the ratio of red to green ﬂuorescence using
the method described previously [14]. After cell treatment, MMP was
determined using JC-1 (15 μM, 30 min, Molecular Probes; monomer:
λex 485 nm, λem 530 nm; aggregate: λex 535 nm, λem 590 nm). Images
acquired frommonomer and aggregateweremerged and viewed under
the Nikon ﬂuorescence microscope (400× ampliﬁcation; Nikon, Japan).
Evaluation of the sub-cellular localization of cytochrome c was done
by using ﬂuorescence imaging of cells double-labeled with MitoTracker
Green (Molecular Probes) and cytochrome c antibody according to the
methods previously reported [13]. After treatment, cells were incubated
with 100 nM MitoTracker Green, ﬁxed with 3% paraformaldehyde,
permeabilized with 0.02% Triton X and blocked with 5% BSA, followed
by treatment with primary rabbit polyclonal cytochrome c antibody
for 2 h at room temperature and Cy2-conjugated goat anti-rabbit
antibody for 1 h. Cellular images were acquired using a ﬂuorescence
microscope (400× ampliﬁcation; Nikon, Japan).
2.9. Determination of caspase9/3 activities
Caspase-3/9 activity in cell lysates was determined using a Caspase-
3 activity kit (Beyotime Institute of Biotechnology, Nantong, China)
according to the manufacturer's protocol. The caspase-3 activity was
normalized by the protein concentration of the corresponding cell
lysate and was expressed in enzymatic units per mg of protein.
2.10. Cell cycle analysis
Treated cells were harvested, ﬁxed and permeabilized with 70%
ethanol, washed with PBS and incubated with 0.5 mL of 50 μg/mL PI
solution containing 20 U/mL RNase A. Data were acquired on the
FL-2A channel to determine the sub-G0/G1 hypodiploid apoptotic
population by ﬂow cytometry. Cell cycle was analyzed using CellQuest
Pro™ software.
2.11. Determination of cardiac ROS production
We evaluated cardiac superoxide production with in situ
dihydroethidium (DHE) staining using the method described previously
[15]. In brief, hearts from mice were excised, immediately embedded inFig. 2. L6H9 inhibits HG-induced inﬂammation and oxidative stress inH9c2 cells. (A–D) L6H9 in
(10 μM) for 1 h were incubatedwith HG (33mM) for 6 h. Cells were harvested and processed fo
the nuclear proteinswere extracted for EMSA (C). (D) H9c2 cells pretreatedwith or L6H9 (10 μM
total RNAs were processed for real-time qPCR assay for TNF-α, IL-6, and COX-2 genes. (E-J) L6
(10 μM) for 1 h were incubated with HG (33 mM) for 12 h. DHE and DCFH-DA probes were loa
(E). Also, after loadedwith the probes, cells were processed to ﬂow cytometry analysis for O2− l
cells were collected and the extracted total RNAs were processed for real-time qPCR assay fo
pretreated with or L6H9 (10 μM) for 1 h were incubated with HG (33 mM) for 6 h. Cells were
(I). Curcumin at 10 μMwas used as a positive comparison in all assays. (* P b 0.05, ** P b 0.01,OCT compound, and cut into 5 μm-thick sections. The section was
incubated with DHE in PBS (10 mmol/L) in a dark and humidiﬁed
container at 37 °C for 45 min. DHE is oxidized upon reaction with
superoxide to ethidium bromide, which binds to DNA in the nucle-
us and ﬂuoresces red. The images were viewed under the ﬂuores-
cence microscope (λex 490 nm, λem610 nm, 400× ampliﬁcation;
Nikon, Japan).2.12. Morphological analysis and rhodamine phalloidin staining
To visualize the morphological change, H9c2 cells were ﬁxed with
4% paraformaldehyde followed by taking phage micrograph using a
light microscope (400× ampliﬁcation, Nikon, Japan). Then the cells
were permeabilizedwith 0.1% Triton-X100 and stainedwith rhodamine
phalloidin at a concentration of 50 μg/mL for 30min at room temperature
and then washed with PBS and detected by ﬂuorescence microscope
(400× ampliﬁcation, Nikon, Japan).2.13. Serum CK-MB determination
Serum samples were then separated for the analysis of cardiac
enzyme CK-MB level using a commercial ELISA kit according to the
manufacturers' instruction (BIOSINO Bio-tech Inc., Shanghai, China).2.14. Immunohistochemistry analysis
Hearts were ﬁxed in 4% paraformaldehyde solution, embedded in
parafﬁn, and sectioned at 5 μm.After dehydration, sectionswere stained
with hematoxylin and eosin (H&E), Masson's trichrome, Sirius red, or
TNF-α antibody, respectively, according to the previously reported
methods. The stained sectionswere then viewedunder theﬂuorescence
microscope (400× ampliﬁcation; Nikon, Japan).2.15. TUNEL staining
Heart tissue sections of 5 μm were used for the terminal
deoxynucleotidyl transferase-mediated dUTP nick end labeling
(TUNEL) apoptosis detection kit (R&D Systems, Minneapolis, MN)
according to the manufacturer's instruction. TUNEL positive cells
were imaged under a ﬂuorescence microscope (400× ampliﬁcation;
Nikon Tokyo, Japan).2.16. Statistical analysis
Each in vitro experiment was performed in a group size of n N 5
independent samples. Representative images from 5 independent
experiments were shown. Data were presented as means ± SEMs. The
statistical signiﬁcance of differences between groups was obtained by
the Student's t test or ANOVA multiple comparisons in GraphPad
Pro5.0 (GraphPad, San Diego, CA). Differences were considered to be
signiﬁcant at P b 0.05 (* or # P b 0.05, ** P b 0.01, and *** P b 0.001).hibits NF-κB activation and inﬂammatory gene expression.H9c2 cells pretreatedwith L6H9
r I-κBα detection bywestern blot analysis (A), p65 immunoﬂuorescence staining (B), and
) for 1 hwere incubatedwith HG (33mM) for 12 h. Cells were collected and the extracted
H9 inhibits ROS generation and activates Nrf2. H9c2 cells that were pretreated with L6H9
ded, respectively, and the ROS positive cells were detected using ﬂuorescencemicroscope
evel (F) and H2O2 level (G), withmean ﬂuorescence intensity (MFI) value. After treatment,
r Nrf2 gene (H) and downstream genes including HO-1, GCLC, and NQO-1 (J). H9c2 cells
lysated and the nuclear extracts were processed to EMSA for the detection of Nrf2 activity
*** P b 0.001).
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3.1. L6H9 mitigated NF-κB-mediated inﬂammatory response in
HG-stimulated H9c2 cells
Our previous publication has demonstrated the anti-inﬂammatory
effects of L6H9 in LPS-stimulated macrophages. It had been reported
that high glucose can induce expression of pro-inﬂammatory cytokine
in a NF-κB-dependent fashion in both macrophages and cardiac cells
[6]. Thus, we examined the effect of L6H9 on the NF-κB activation. Incu-
bation with high glucose (HG, 33mM) for 6 h in H9c2 cells signiﬁcantly
induced IκBα degradation (Fig. 2A) and translocation of NF-κB p65
subunit from the cytosol to the nucleus (Fig. 2B), while these changes
were remarkably inhibited by the pretreatment with L6H9 at 10 μM.
The NF-κB-inhibiting effect of L6H9 in HG-stimulated H9c2 cells was
further validated by a DNA-binding EMSA assay (Fig. 2C). In addition,
real-time qPCR analysis showed that there were marked increases in
the expression of pro-inﬂammatory genes including TNF-α, IL-6, and
COX2 in H9c2 cells exposed to HG, while, these overproductions were
signiﬁcantly attenuated by pretreatment with 10 μM L6H9 (Fig. 2D).
L6H9 showed a comparable anti-inﬂammatory effect with the positive
comparison curcumin (Fig. 2A–D).
3.2. L6H9 inhibited HG-induced ROS generation via augmenting anti-
oxidant Nrf2 pathway in H9c2 cells
Oxidative stress has been implicated in the pathogenesis of DCM
[16]. As shown in Fig. 2E, HG (33 mM) treatment for 12 h induced
signiﬁcant ROS generation including increased H2O2 level and increased
O2− level in H9c2 cells detected with DCFH-DA and DHE probe, respec-
tively, whichwas further conformed by ﬂow cytometry analysis (Fig. 2F
andG). However, pretreatment of curcumin (10 μM)or L6H9 (10 μM) in
H9c2 cells exposed toHG (33mM) signiﬁcantly attenuated HG-induced
ROS generation (Fig. 2E–G). In addition, L6H9 showed stronger
inhibition against both H2O2 and O2− generation than curcumin at the
same concentration.
The transcription factor NFE2-related factor 2 (Nrf2) is a main
regulator of cellular detoxiﬁcation responses and redox status [17].
Nrf2 could bind to antioxidant-responsive element (AREs) in the
genes encoding antioxidant enzymes, such as NADPH quinine oxidore-
ductase (NQO-1), heme oxygenase-1 (HO-1), and glutamate cysteine
ligase catalytic subunit (GCLC), and increase their expression.Weexam-
ined the effects of L6H9 on Nrf2 signaling pathway. As shown in Fig. 2H
and I, HG (33mM) signiﬁcantly down-regulated theNrf2mRNA expres-
sion and Nrf2 DNA-binding activity in H9c2 cells, as determined by real-
time qPCR and EMSA, respectively. Pretreatment of H9c2 cells with
L6H9 (10 μM) signiﬁcantly increased Nrf2 mRNA expression and Nrf2
activity (Fig. 2H and I). In consistent with Nrf2 activation, real-time
qPCR analysis revealed that L6H9 (10 μM) pretreatment signiﬁcantly
up-regulated the expression of Nrf2-downstream anti-oxidant genes
including HO-1, NQO-1, and GCLC in H9C2 cells exposed to high glucose
(33 mM) for 12 h (Fig. 2J). Interestingly, curcumin at the concentration
of 10 μM only showed a moderate regulating effect in Nrf2 activity
(Fig. 2H–J). Thus, unlike the anti-inﬂammatory activity, L6H9 displays
much stronger anti-oxidative activity than curcumin at the levels of
both ROS generation and Nrf2 signaling.
3.3. L6H9 attenuated HG-induced mitochondrial injury and cell apoptosis
in H9c2 cells
In vitro studies had reported that HG-induced oxidative stress
contributed to the apoptosis of cardiac cells, which is accompanied
with the activation of mitochondria-dependent pro-apoptotic path-
ways, involving the loss of mitochondrial membrane potential (MMP),
release of cytochrome c from mitochondrial, and activation of
caspases-9 and -3 [18]. Alterations in MMP were detected using JC-1ﬂuorescent dye. As shown in Fig. 3A, untreated control cells exhibited
numerous brightly stained mitochondria that emitted red ﬂuorescence,
representing a normally hyperpolarized membrane potential. After
treatment with HG (33 mM) for 24 h, H9c2 cells showed green JC-1
monomers, indicating a gradual dissipation of MMP. However, cells
pretreatedwith L6H9 (10 μM) emitted reddish andorange ﬂuorescence,
indicating a marked protection on MMP loss from HG damage. The
release of cytochrome c from mitochondria was then determined using
mitochondria/cytochrome c double staining. In untreated cells, cyto-
chrome c immunoreactivity was co-localized in the mitochondria. After
exposure of H9c2 cells toHG for 24 h, the cells exhibited cytochrome cdif-
fusely distributed throughout the cytoplasm and a decrease in
mitochondrial-associated cytochrome c, indicating that cytochrome c
was released from mitochondrial to the cytoplasm, while pretreatment
with L6H9 signiﬁcantly inhibited the HG-induced release of cytochrome
c frommitochondria (Fig. 3B). The effect of L6H9 on the cytochrome c re-
leasewas further conﬁrmed bywestern blot analysis using the cytoplasm
proteins (Fig. 3C). Bcl-2 family proteins play a critical role in the
mitochondria-mediated cell apoptosis [19].Western blot analysis also re-
vealed that L6H9 signiﬁcantly reducedHG-induced pro-apoptotic Bax ex-
pression and reversed HG-decreased anti-apoptotic Bcl-2 expression
(Fig. 3C). We also performed a time-course response of HG stimulation
on cell apoptosis ranging from 6 hours to 48 h, using Annexin V staining
method followed by ﬂow cytometry analysis. Figure S1A showed that
the ratio of Annexin V-positive cells reached a peak at 24 h and showed
no signiﬁcant change during subsequent 24 h–48 h after HG treatment.
Thenwe examined the effects of curcumin and L6H9 on cell apoptosis in-
duced by HG at the 24 h time point using themethods of both Annexin V
staining and cleaved-caspase3 western blot analysis. Figure S1B showed
that curcumin and L6H9 reduced the cell apoptosis in HG-stimulated
H9c2 cells; and Figure S1C showed that curcumin and L6H9 inhibited
HG-induced caspase-3 activation. Subsequently, an increase in the
caspase-9 and caspase-3 activity were also observed in H9c2 cells after
HG (33 mM) stimulation for 24 h, while either L6H9 or curcumin was
able to abrogate these caspase activity (Fig. 3D and E). Finally, the cell
cycle analysis was performed using ﬂow cytometry. As shown in Fig. 3F,
the apoptotic population in the sub-G0 phage signiﬁcantly increased in
HG-treated cells (7.23 ± 1.64%), while pretreatment with 10 μM L6H9
signiﬁcantly reduced apoptotic population in sub-G0 phage (4.41 ±
1.55%). Also, L6H9 showed a stronger anti-apoptotic effect than curcumin
at the same concentration (Fig. 3A–F).
3.4. L6H9 attenuatedHG-induced pro-ﬁbrotic response and pro-hypertrophic
response in H9c2 cells
We also tested the effect of L6H9 on pro-ﬁbrotic markers in
HG-stimulated H9c2 cells. It was found that the protein and mRNA
expression of pro-ﬁbrotic genes including TGF-β, collagen 1 and CTGF
were signiﬁcantly increased after 12-h HG incubation, as indicated
from both immunoﬂuorescence staining (Fig. 4A and B) and real-time
qPCR analysis (Fig. 4C), respectively. However, these changes were
signiﬁcantly attenuated by pretreatment with either L6H9 (10 μM) or
the positive control curcumin (10 μM) (Fig. 4A–C).
Cardiomyocyte hypertrophy also plays an important role in the path-
ological development of DCM. Thus, the effect of L6H9 on cardiac cell hy-
pertrophy was examined by measuring the cell surface area using light
microscopy and rhodamine phalloidin staining. Cells were pretreated
with L6H9 for 1 h and then incubated with HG (33 mM) for 12 h. As
shown in Fig. 4D, L6H9 signiﬁcantly suppressed HG-induced increase in
cardiac cell size. Next, the mRNA levels of cardiac hypertrophy marker
genes including ANP, BNP, and β-MyHC were determined by real-time
qPCR. Fig. 4C showed that the expression of these three proteins was
signiﬁcantly higher in HG-treated cells compared to the vehicle control,
and pretreatment with either L6H9 or curcumin signiﬁcantly inhibited
the increased expression of ANP, BNP, and β-MyHC. L6H9 reached com-
parable anti-ﬁbrosis and anti-hypertrophy effects with curcumin in vitro.
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Fig. 3. L6H9 attenuatesHG-inducedmitochondrial injury and apoptosis inH9c2 cells. H9c2 cells pretreatedwith L6H9 (10 μM) for 1 hwere incubatedwithHG (33mM) for 24h. Cellswere
processed to JC-1 staining for mitochondrial membrane potential analysis (A), and anti-cytochrome C staining, Mito-T green ﬂuorescence staining, and DAPI staining for detecting the
translocation of cytochrome C from the mitochondria to the cytosol (B). (C-E) L6H9 affects apoptotic proteins. After treatment, cells were lysates and the extracted total proteins were
processed western blot analysis (C) and caspase-9 (D) and caspase-3 (E) activity assay. (F) After treatment, ﬂow cytometry assay for DNA content was performed. Curcumin at 10 μM
was used as a positive comparison in all assays. (* P b 0.05, ** P b 0.01, *** P b 0.001).
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in diabetic mice
Thenatural curcuminwith both anti-inﬂammatory and anti-oxidative
effects was used as a positive comparison. Since curcumin is of extremely
high safety and a previous publication showed that curcumin adminis-
trated orally at 50 mg/kg/day in mouse models could protect obesity
cardiomyopathy [20], we chose the dosage of 50mg/kg/day for curcumin
oral administration in STZ-induced diabetic mice. STZ-induced diabetic
mice (STZ-DM1) exhibited increased blood glucose level (Figure S2A)
and relatively stable body weight (Figure S2B) during the animal
experiment. Either curcumin (50 mg/kg) or L6H9 (20 mg/kg) treatmentfor 8 weeks resulted in no signiﬁcant differences in blood glucose levels
between the STZ-DM1 group and curcumin/L6H9-treated groups
(Figure S2A). Similarly, therewas no signiﬁcant difference in bodyweight
between the STZ-DM1 group and curcumin/L6H9-treated groups
(Figure S2B). These data suggest that L6H9 could not attenuate type 1
diabetic symptom in mice.
3.6. L6H9 decreased diabetes-induced cardiac remodeling and ﬁbrosis
The myocardial structure was examined by H&E staining, Sirius red
staining and Masson trichrome staining, respectively. H&E staining
showed that diabetic hearts displayed structural abnormalities,
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Fig. 4. L6H9 attenuates HG-induced ﬁbrosis and hypertrophy in H9c2 cells. H9c2 cells pretreated with L6H9 (10 μM) for 1 h were incubated with HG (33 mM) for 24 h. Immunoﬂuores-
cence staining for TGF-β (A) and collagen 1 (B) in the cells were performed; representative images for cell morphology analysis were obtained using light microscopy and rhodamine-
phalloidin/DAPI immunoﬂuorescence staining, respectively (D); and the real-time qPCR analysis for pro-ﬁbrotic (C) and pro-hypertrophic (E) genes expression was carried out (C).
Curcumin at 10 μMwas used as a positive comparison in all assays. (*, vs HG group; #, vs DMSO group; # and * P b 0.05, ** P b 0.01, *** P b 0.001).
1236 P. Zhong et al. / Biochimica et Biophysica Acta 1852 (2015) 1230–1241including broken ﬁbers, deranged cellular structures, the existence of
foci with necrotic myocytes, increased cardiomyocyte transverse
cross-sectional area, and the inﬁltration of inﬂammatory cells. There
was no signiﬁcant evidence of these abnormalities in the hearts of dia-
betic mice that had been treated with L6H9 or curcumin (Fig. 5A). In
consistent with the transverse section H&E staining, real-time qPCR
analysis revealed that L6H9 or curcumin signiﬁcantly reduced the over-
expression of the hypertrophic marker BNP in the diabetic hearts
(Fig. 5B). L6H9 administration also remarkably decreased the serum
heart-type creatinine kinase MB isoenzyme (CK-MB), a biochemical in-
dicator of myocardial injury, in diabetic mice (Fig. 5C). However,
curcumin did not show the similar effect on CK-MB level. Since other or-
gans such as liver and skeletal muscles also release CK-MB, the serum
CK-MB level may be affected by the injuries in liver and skeletal muscle
in diabetic mice. According to Fig. 5C, it is also possible that L6H9 can
protect multiple organs in diabetic mice while curcumin only protects
the heart.We already added the corresponding discussion in the revised
manuscript. Additionally, obvious ﬁbrosis in the hearts of STZ-DM1Fig. 5. L6H9 and curcumin attenuate diabetes-induced cardiac pathological changes andﬁbrosis
in the formalin-ﬁxedmyocardial tissues (400×magniﬁcation). (B) ThemRNAexpression of BNP
indicated kit. (D) Representative images for Sirius red staining andMasson staining in the forma
diac ﬁbrosis (400× magniﬁcation). (E) Western blot analysis for the TGF-β/collagen 1 protein e
myocardial tissues was determined by real-time qPCR. Six to eight mice in each group were usgroup was observed, as well as destroyed and disorganized collagen
network structure in the interstitial, detected by Sirius red staining
and Masson staining (Fig. 5D). These ﬁbrotic changes in the diabetic
hearts were signiﬁcantly mitigated when mice treated with L6H9 or
curcumin (Fig. 5D). Western blot analysis further revealed the signiﬁ-
cant decrease in the expression of pro-ﬁbrotic proteins TGF-β and colla-
gen 1 in the diabetic hearts by L6H9 or curcumin administration
(Fig. 5E). Similar anti-ﬁbrosis results were also observed at the mRNA
level when determined by real-time qPCR assay (Fig. 5F).
3.7. L6H9 attenuated diabetes-induced myocardial oxidative stress and
inﬂammation
We further detected the anti-oxidative and anti-inﬂammatory effects
of L6H9 in diabetic hearts. DHE staining showed that therewas signiﬁcant
increase inO2− generation in the hearts of diabeticmice, compared to the
vehicle mice (Fig. 6A). Curcumin or L6H9 treatmentmarkedly attenuated
the diabetes-induced O2− generation (Fig. 6A). Fig. 6B showed thatin STZ-inducedmice. (A) Representative images for the hematoxylin–eosin staining (H&E)
in themyocardial tissues by real-time qPCR. (C) SerumCK-MB levelwas determined using
lin-ﬁxedmyocardial tissues indicating collagen deposition and implying the extent of car-
xpression in the myocardial tissues. (F) The mRNA expression of pro-ﬁbrotic genes in the
ed for above analysis. *, P b 0.05 versus STZ-DM1; #, P b 0.05 versus vehicle control.
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reversed by curcumin or L6H9 treatment for 8weeks. Real time PCR anal-
ysis revealed that L6H9 or curcumin treatment also altered the expression
proﬁle of Nrf2-downstream anti-oxidative genes, including HO-1, NQO-1,
and GCLC, in diabetic hearts (Fig. 6C).
Regarding to the in vivo anti-inﬂammatory effect of L6H9, we ﬁrstly
determined the cardiac TNF-α expression by immunohistochemical
staining, which showed that the increase in TNF-α level in diabetic
hearts was signiﬁcantly reduced by the treatment with L6H9 or
curcumin (Fig. 6D). The result on TNF-α expression proﬁle was further
validated by western blot analysis (Fig. 6E). In addition, L6H9 also re-
markably inhibited diabetes-induced IκB degradation in diabetic hearts,
indicating NF-κB activation was suppressed (Fig. 6E). Finally, the levels
of three pro-inﬂammatory genes TNF-α, IL-6, and cyclooxygenase 2
(COX2) were detected in the hearts of each group by real-time qPCR
assay. Fig. 6F showed that either L6H9 or curcumin signiﬁcantly attenu-
ated the pro-inﬂammatory gene transcription induced by diabetes.
3.8. L6H9 mitigated cell apoptosis in the diabetic myocardium
Apoptosis in the heart tissues were detected by TUNEL staining and
western blot. In diabetic myocardium, there was marked increase in
TUNEL-positive apoptotic cells (Fig. 7A) and pro-apoptotic protein Bax
expression (Fig. 7B), and decreased anti-apoptotic Bcl-2 level (Fig. 7B);
all these changes in diabetes were signiﬁcantly attenuated by L6H9 or
curcumin treatment.
4. Discussion
Accumulating evidence suggests that increased oxidative stress and
various pro-inﬂammatory cytokines coupled with ﬁbrosis and activa-
tion of cell death pathways play pivotal roles in the development of
complex biochemical, mechanical, and structural alterations associated
with diabetic cardiomyopathy [1]. Consistent with previous reports, the
development of diabetic cardiomyopathy in type 1 diabetic mouse
models was characterized by a series of histopathological changes in
the hearts, accompanied with increased inﬂammation, oxidative stress,
cardiac cell death, ﬁbrosis, hypertrophy (Figs. 5–7). Similar results were
reﬂected in the cellular level and were observed in HG-treated H9c2
cells (Figs. 2–4). However, in spite of the accumulating knowledge
obtained during the past decades, the treatment of diabetic cardiomy-
opathy still remains poor and largely symptomatic.
A number of natural products were used for the treatment of cardio-
vascular diseases for decades. Recently, a natural compound cannabidiol
has been shown to have great therapeutic potential in the treatment of
DCM by attenuating oxidative/nitrative stress, inﬂammation, cell death
and ﬁbrosis [5]. Previously, our lab has discovered a new chalcone
derivative, L6H9, which exhibited signiﬁcant therapeutic effects against
LPS-induced inﬂammation both in vitro and in vivo [11]. In the present
study, we have evaluated the effects of L6H9 treatment on myocardial
histopathology, inﬂammation, oxidative stress, cell death, and interre-
lated signaling pathways, using a mouse model of type 1 diabetic
cardiomyopathy or cardiac cells exposed to HG.
Firstly, L6H9 inhibited the inﬂammatory response in cardiomyocytes
induced by HG or hyperglycemia. Elevated inﬂammatory cytokine level
exists not only in the myocardium of diabetic animal models, [21] but
also in the serum of diabetic patients, even in those patients with
good glycemic control [22]. Chronic and sustained presence of cytokines
leads tomyocyte phenotype transition and activation ofmatrixmetallo-
proteinases that modiﬁes interstitial matrix, further augmenting the
ﬁbrosis and remodeling process [23]. Several anti-inﬂammatory medi-
cations have been reported to have important roles in the prevention
of diabetic cardiomyopathy [6,24]. In this report, L6H9was demonstrat-
ed to decrease the HG/diabetes-induced pro-inﬂammatory cytokine
expression both in vitro (Fig. 2D) and in vivo (Fig. 6F), which contributes
to its protection from DCM. As a key transcription factor to controlinﬂammation, NF-κB was demonstrated to play a pivotal role in the
development of DCM [25]. There is growing evidence supporting that
NF-κB signaling pathway is activated in DCM in vivo and in cardiac
cells induced by HG condition in vitro [6,21]. Our results are also in
agreement with previous studies demonstrating enhanced activation
of NF-κB in DCMmodels and demonstrating that pharmacological inhi-
bition of NF-κB attenuates the expression of cardiac inﬂammatory
markers, such as TNF-a, IL-6, and COX-2, associated with DCM.
In addition to inﬂammation, oxidative stress is an important initial
phage for the pathogenesis of DCM [16]. ROS has also been implicated
in all stages of the development of heart failure, fromcardiac hypertrophy
to ﬁbrosis, contractile dysfunction, and heart failure [26]. In diabetic
heart, hyperglycemia, the fatty acid oxidation pathway, and the cytosolic
storage of fatty acid and glucose/fatty acid derivatives aremajor inducers
of reactive oxygen species [27]. Evidence has also demonstrated that in-
creased expression and activation of nicotinamide adenine dinucleotide
phosphate oxidases which accounting for mitochondrial source of ROS
play a pivotal role inDCM [28]. Targeting redox stressmay represent a fu-
ture strategy for combating the ever-increasing incidence of heart injury
in the diabetic population [29]. Treatment with L6H9 was able to inhibit
HG/hyperglycemia-induced ROS generation effectively. Recent evidence
supported an emerging role of Nrf2 activation in diabetic cardiomyopa-
thy, [30] in addition to its already established role in mediating cell
death during myocardial ischemic-reperfusion injury [31]. We found
that HG treatment or diabetes signiﬁcantly down-regulated the expres-
sion and activity of Nrf2 both in vitro (Fig. 2H–I) and in vivo (Fig. 6B),
which was consistent with previous reports [32]. Nrf2 up-regulation
and activation have been shown to be involved in the protective effects
of several compounds with antioxidant activity against DCM [33,34].
Nrf2 activators have also been used to attenuate the pathology of DCM
[32]. It has been reported that chalcones and their derivatives can activate
Nrf2 and protect cells against oxidative stress [35]. Here, we found that
L6H9 also increased the activation and expression of Nrf2, followed by
up-regulation of Nrf2-downstream anti-oxidative proteins, both in vitro
and in vivo, indicating that Nrf2 may mediate the anti-oxidative activity
and anti-DCM effect of L6H9.
Activation of NF-κB and ROS has been implicated to the cardiac cell
apoptosis, ﬁbrosis, and hypertrophy in HG condition [16,36]. Apoptosis
induced by hyperglycemia is considered as one of the hallmarks of DCM
and has been reported to be related with increased oxidative stress,
inﬂammation, ER stress, and mitochondrial dysfunction [37,38]. The
emergence of mitochondria as critical regulators of cardiac myocyte
survival and death has revolutionized the ﬁeld of cardiac biology in
recent years. It is now recognized that mitochondrial dysfunction may
play a crucial role in the pathogenesis of multiple cardiac diseases
[19]. The important role of mitochondrial in the development of
STZ-induced diabetic cardiomyopathy was also supported by J. Ren's
group [39]. Our study found that HG/hyperglycemia induced the loss
of mitochondrial membrane potential, the release of cytochrome c,
and subsequent activation of caspase-9/3 and apoptosis (Figs. 3
and 7). All of these pathological alterations were signiﬁcantly reversed
by L6H9 treatment (Figs. 3 and 7), which may result from the anti-
oxidative and anti-inﬂammatory action of L6H9. Cardiac ﬁbrosis and
hypertrophy are also two important pathological process of DCM. It
has been demonstrated that high glucose or diabetes can induce the
expression of a series of pro-ﬁbrotic genes both in vitro and in vivo
[40–42]. These abnormities were all attenuated by treatment with
L6H9, suggesting that L6H9 has anti-ﬁbrotic activity in DCM. Oxidative
stress and inﬂammatory cytokines contribute to cardiac hypertrophy in
DCM. In the present study, the anti-oxidative and anti-inﬂammatory ef-
fects of L6H9 also resulted in the attenuation of cardiac hypertrophy
both in vitro and in vivo (Figs. 4 and 5).
In this study, the positive control curcumin also showed comparable
effects with L6H9 both in vitro and in vivo. However, the dosage of
curcumin in animal study is 2.5-fold higher than that of L6H9, which
is also consistent with the well-known metabolic defect of curcumin
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Fig. 6. L6H9 and curcumin attenuate diabetes-inducedmyocardial oxidative stress and inﬂammation. (A) Representative images for DHE staining using the frozen section of heart tissues
as described in Methods (400× magniﬁcation). (B) Nrf2 expression in heart tissues was determined by western blot analysis. (C) The mRNA expression of anti-oxidant genes in heart
tissues was determined by real-time qPCR. (D) Representative images for the histochemical staining for TNF-α accumulation in the formalin-ﬁxed heart tissues (400× magniﬁcation).
(E) Western blot analysis for the protein expression of TNF-α and I-κBα in myocardial tissues was performed. (F) The mRNA expression for TNF-α, IL-6 and COX2 in heart tissues was
detected by real-time qPCR. Six to eight mice in each group were used for above analysis. *, P b 0.05, **, P b 0.01 versus STZ-DM1; #, P b 0.05 versus vehicle control.
1239P. Zhong et al. / Biochimica et Biophysica Acta 1852 (2015) 1230–1241[43]. Although curcumin shows multiple pharmacological activities in
the treatment of a variety of diseases, the poor pharmacokinetic proﬁle
signiﬁcantly limits its clinical application. Thus, L6H9 is more promising
candidate than curcumin and deserves to be development for the
treatment of DCM.
The current work vigorously demonstrated that hyperglycemia-
induced inﬂammation and oxidative stress mediated the pathogenesis
and development of diabetic cardiomyopathy. Multiple pathological
and functional alterations includingmitochondrial dysfunction, ﬁbrosis,
hypertrophy, and cardiomyocyte apoptosis could be attenuated by the
inhibition of inﬂammation and ROS at both cellular and animal levels.Thus, these results strongly suggest that targeting NF-κB and Nrf2 may
be a good therapeutic strategy in treating diabetic cardiomyopathy.
Targeting reduction of ROS or increasing antioxidant activity would
intuitively represent novel therapeutic modalities against diabetic
cardiomyopathy. However, clinical studies have been unable to translate
these promising scientiﬁc data to the bedside, and several larger random-
ized trials were unable to report any beneﬁts of antioxidant cardiovascu-
lar outcome in high-risk individuals [44]. It should be noted that many
factors such as the type of treatment, metabolic characteristics, lipid
proﬁle, and other individual differences may affect the progress of
development of diabetic cardiomyopathy. More importantly, multiple
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Fig. 7. L6H9 and curcuminmitigate apoptosis in diabeticmyocardium. (A) Representative images for TUNEL staining in heart tissue sections. (B)Western blot analysis for the expression of
apoptosis-related proteins inmyocardial tissues was performed. Six mice in each groupwere used for above analysis. *, P b 0.05, versus STZ-DM1; #, P b 0.05 versus vehicle control. (C) A
schematic illustration for the prevention of L6H9 from diabetes/HG-induced injury in cardiomyocytes and heart.
1240 P. Zhong et al. / Biochimica et Biophysica Acta 1852 (2015) 1230–1241mechanisms have been implied in the pathogenesis of DCM, such as
inﬂammation andoxidative stress. The oxidative stress and inﬂammatory
pathways in diabetic cardiomyopathy are closely interrelated. They
interact and crosslink throughout the complicated process of DCM [45].
Thus, independently blocking each pathway may be not effective for
the treatment of DCM. Research over the past several years have
developed many mono-targeted therapies for the prevention and
treatment of DCM or other diabetic complications, but it still remains
one of the most fatal diseases in the world. Our results further suggest
the tremendous therapeutic potential in treating diabetic cardiovascular
complications by attenuating both the initial oxidative stress and inﬂam-
mation induced by hyperglycemia or diabetes. Agents including L6H9
and some natural active compounds with both anti-oxidant and anti-
inﬂammatory properties may attract more attention for the treatment
of this disease.
5. Conclusions
In conclusion, the ﬁndings of the present study, both in vitro and
in vivo, demonstrate thepreventive role of L6H9 against oxidative stress,
inﬂammation, mitochondrial dysfunction, apoptosis, hypertrophy and
ﬁbrosis in DCM (Fig. 7C). The beneﬁcial actions of L6H9 are closely
associated with its ability to inhibiting HG-induced oxidative stress
and inﬂammation via increasing Nrf2 and inhibiting NF-κB, respectively
(Fig. 7C). Although continued research is needed to examine the under-
lying molecular target of L6H9, this clearly suggests the therapeutic
application of L6H9 in the treatment of diabetic complications includingDCM. In addition, Nrf2 and NF-κB, regulating the oxidative stress and
inﬂammation respectively, mediate the hypertrophic, apoptotic, and ﬁ-
brotic effects of both HG-stimulated cardiac cells and diabetes-induced
hearts. These results provide a deeper understanding of the regulatory
role of Nrf2 and NF-κB in DCM, indicating that they may be important
therapeutic targets for diabetic complications.Conﬂicts of interest
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